Quantcast

Latest Dana-Farber Cancer Institute Stories

2011-08-03 15:00:00

SOUTH SAN FRANCISCO, Calif. and NORWALK, Conn., Aug. 3, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) and the Multiple Myeloma Research Foundation (MMRF) today announced the initiation of an expanded access program for carfilzomib, a selective, next-generation proteasome inhibitor. The Carfilzomib Myeloma Access Program (C-MAP) will include eligible patients in the United States (U.S.) with relapsed and refractory multiple myeloma. Expanded access programs make...

c011666b724d316fd6682f5fbce6c79b
2011-07-31 07:22:28

Salk Institute and Dana Farber Cancer Institute researchers contribute to production of largest-ever map of plant protein interactions Science usually progresses in small steps, but on rare occasions, a new combination of research expertise and cutting-edge technology produces a 'great leap forward.' An international team of scientists, whose senior investigators include Salk Institute plant biologist Joseph Ecker, report one such leap in the July 29, 2011 issue of Science. They describe...

2011-07-21 07:45:00

BOSTON, July 21, 2011 /PRNewswire/ -- Zipcar, Inc. (Nasdaq: ZIP), the world's leading car-sharing network, is taking on the 32nd annual Pan-Massachusetts Challenge (PMC) with a team of 25 riders and a goal of raising $150,000 to support cancer research and treatment. This year marks Zipcar's fifth consecutive year of participation in the PMC. Since 2007, Team Zipcar has raised more than $535,000 to benefit adult and pediatric cancer research and treatment at Dana-Farber Cancer Institute....

2011-07-20 17:16:00

Promising results of PI3K inhibitor study discussed at ASCO annual meeting SCOTTSDALE, Ariz., July 20, 2011 /PRNewswire-USNewswire/ -- A new drug targeting the PI3K gene in patients with advanced breast cancer shows promising results in an early phase I investigational study conducted at Virginia G. Piper Cancer at Scottsdale Healthcare, according to a presentation by oncologist Dr. Daniel D. Von Hoff at the 47th annual meeting of the American Society of Clinical Oncology (ASCO). The drug...

35f3a691ee434334c1248708e09e4147
2011-07-19 13:05:00

Cancer biologists at MIT have identified a new lung cancer gene that drives the spread of the deadly condition. MIT reported that a major challenge for cancer biologists is determining which genetic mutations found in a cancer cell are most important for driving the cancer's spread. The scientists used a new technique called whole-genome profiling to pinpoint the gene that drives progression of small cell lung cancer, which accounts for about 15 percent of lung cancer cases. Alison Dooley,...

2011-07-14 16:08:05

Wanderlust in a person can be admirable or romantic. In a cancerous tumor, it may be lethal. Most deaths from cancer result from tumor cells that have strayed from their original location to insinuate their way into distant tissues. With few exceptions, however, doctors have little way of determining whether a newly formed tumor is more likely to remain idle or send invader cells to other parts of the body. In a study published in the July 12 issue of the journal Cancer Cell, scientists at...

2011-07-11 20:40:19

Although it sounds like a case of gender confusion on a molecular scale, the male hormone androgen spurs the growth of some breast tumors in women. In a new study, scientists at Dana-Farber Cancer Institute provide the first details of the cancer cell machinery that carries out the hormone's relentless growth orders. The study, published the journal Cancer Cell on July 12, provides scientists with several inviting targets "“ cell proteins that snap into action in response to androgen...

2011-07-11 11:00:00

Mixed lineage leukemias rely on epigenetic changes to grow and survive; new molecule shows promise for targeting these changes therapeutically BOSTON, July 11, 2011 /PRNewswire-USNewswire/ -- A difficult-to-treat form of childhood leukemia relies on changes in the structure of DNA - so-called epigenetic changes - to wreak genomic havoc within white blood cells, according to one of two studies conducted by a research team at Children's Hospital Boston and Dana-Farber Cancer Institute....

2011-07-11 07:00:00

WHITE PLAINS, N.Y., July 11, 2011 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) is taking an aggressive and proactive approach to tackling the challenge of improving outcomes for cancer patients with particularly urgent needs. (Logo: http://photos.prnewswire.com/prnh/20110215/NY48642LOGO ) Earlier this year, LLS identified three underdeveloped but promising areas of research and sought proposals to help stimulate more academic research in these areas: the malignant stem...

2011-06-30 13:41:10

Researchers at Dana-Farber Cancer Institute have demonstrated a molecular strategy they say could make a much larger variety of tumors treatable with PARP inhibitors, a promising new class of cancer drugs. Currently, the role of PARP inhibitors has mainly been restricted to cancers whose cells lack functioning versions of the damage-repair proteins BRCA1 or BRCA2 -- chiefly certain breast and ovarian cancers. In a paper published online by Nature Medicine, Geoffrey Shapiro, MD, and colleagues...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related